Business Context and Reporting Period
This Form 8-K Current Report was filed by Core Scientific, Inc. on September 6, 2024. The filing primarily addresses the departure of the company's Chief Financial Officer and the associated transition arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the departing executive:
- Base Salary: $500,000 (retroactively effective May 2, 2024).
- Retention Bonus: Up to $500,000, contingent on employment through December 31, 2024.
- Equity Grant: 318,613 time-based restricted stock units (RSUs) vesting on March 31, 2025.
Material Changes
The material change reported is the resignation of Denise Sterling, Executive Vice President and Chief Financial Officer, effective September 5, 2024. The company has initiated a nationwide search for a successor. Ms. Sterling will remain employed until the earlier of May 1, 2025, or the hiring of her successor.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. Management commentary is limited to the executive transition, noting that the departure is not the result of any disagreement regarding the company's operations, policies, or accounting procedures. The primary contingency is the successful recruitment of a new CFO to ensure a smooth transition of duties.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Review the full text of the Transition and Separation Agreement (Exhibit 10.1) for specific conditions regarding the retention bonus and accelerated vesting.
- Monitor subsequent filings for the appointment of the new CFO and any interim financial leadership arrangements.
- Check for any impact on the company's internal controls or financial reporting processes during the transition period.